Colgate-Palmolive Co (CL)
Fair bewertetFundamental
55
Kurs
$85.02
Marktkapitalisierung
$68.97B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals. It also offers pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand; and a fresh pet food sold to pet specialty and other retailers in Australia under Prime100 brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users
P&G sells to the same supermarket shoppers in nearly every Colgate category, with Crest and Oral-B against Colgate toothpaste and toothbrushes, Olay and Old Spice against Palmolive and Softsoap, and Dawn and Tide against Colgate's home-care lines.
Church & Dwight targets the same US household shopper with TheraBreath mouthwash and Arm & Hammer toothpaste against Colgate's oral care, and with Arm & Hammer and OxiClean against its cleaning brands.
Unilever fights Colgate for the same shelf space in oral care (Closeup, Pepsodent) and personal care (Dove, Lifebuoy), above all in the emerging markets that generate a large share of Colgate's sales.
Haleon is the main rival in premium therapeutic oral care, where Sensodyne, Parodontax and Polident compete directly with Colgate Sensitive, Colgate Total and Colgate's denture-care products, often on pharmacist and dentist recommendation.
Through Purina and Purina Pro Plan Veterinary Diets, Nestlé is the largest player in the pet food aisles and veterinary clinics where Colgate's Hill's Science Diet and Prescription Diet earn roughly a quarter of group sales.
Reckitt competes for the same home-care and hygiene budget, with Lysol, Finish and Air Wick facing Colgate's Ajax, Fabuloso, Axion and Suavitel across the US, Europe and Latin America.
Bilanz & Liquidität
Umsatz
$21.05B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$2.04B
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$3.63B
Gesamtes Eigenkapital
$54M
Gesamtverbindlichkeiten
$15.96B
Current Ratio
1.03
Zinsdeckungsgrad
12.32
Schulden/EBITDA
1.99
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$71.98
Aktueller Kurs
$85.02
Sicherheitsmarge
-18.1%
Innerer-Wert-Spanne
$46.79 - $97.17
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
33.72
ROE
3948.1%
P/B-Verhältnis
288.20
P/FCF
17.63
Bruttomarge
60.4%
ROIC
23.2%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
23.2%
WACC
7.5%
ROIC − WACC
+15.8 pp
Der ROIC übersteigt die Kapitalkosten: Das Unternehmen schafft Wert für die Aktionäre.
Fundamentalanalyse-Kriterien
Bestanden (14)
- ROIC 23.2%
- Gross Margin 60.4%
- P/FCF 17.63
- Operating Margin 14.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 631.1%
- Analyst Consensus 65% Buy
- Earnings Quality (OCF/NI) 2.19
- Share Dilution -1.5%
Nicht bestanden (12)
- EPS shows upward trend
- EPS CAGR -1.08%
- Price CAGR 2.87%
- P/B Ratio 288.20
- Debt/Equity ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 4.3%
- Earnings Surprise avg 0.4%
- Net Margin Trend 9.7% vs 14.5%
- Piotroski F-Score 4/9
Nicht verfügbar (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Noel R. Wallace | Chairman, CEO & President | 61 |
| Mr. Stanley J. Sutula III | Chief Financial Officer | 59 |
| Mr. Panagiotis Tsourapas | COO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | 60 |
| Mr. Shane Grant | Chief Operating Officer of Americas | 50 |
| Mr. Stephan Habif | Chief Technology Officer | - |
| Mr. David Foster | Chief Information Officer | - |
| Mr. John Faucher | Chief Investor Relations Officer and Executive VP of M&A | - |
| Ms. Betsy Fishbone | EVP, Chief Legal Officer & Secretary | - |
| Mr. Eutychus Karuru | Executive Vice President of Internal Audit & Compliance | - |
| Mr. Dana Bolden | Chief Communications Officer | 57 |
Prüfungsrisiko
3
Vorstandsrisiko
5
Vergütungsrisiko
4
Aktionärsrechterisiko
2
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-23
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-07-31
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-07-31
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for CL, sourced from Markets Gazette.